ACADIA PHARMACEUTICALS ($ACAD) posted quarterly earnings results on Wednesday, August 6th. The company reported earnings of $0.16 per share, beating estimates of $0.14 by $0.02. The company also reported revenue of $264,570,000, missing estimates of $267,119,262 by $-2,549,262.
You can see Quiver Quantitative's $ACAD stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ACADIA PHARMACEUTICALS Insider Trading Activity
ACADIA PHARMACEUTICALS insiders have traded $ACAD stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $ACAD stock by insiders over the last 6 months:
- LAURA BREGE sold 14,446 shares for an estimated $314,633
- MARK C. SCHNEYER (EVP, CHIEF FINANCIAL OFFICER) has made 0 purchases and 5 sales selling 12,150 shares for an estimated $210,697.
- JAMES KIHARA (PRINCIPAL ACCOUNTING OFFICER) has made 0 purchases and 6 sales selling 7,925 shares for an estimated $152,759.
- ELIZABETH A. GAROFALO sold 4,919 shares for an estimated $89,673
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ACADIA PHARMACEUTICALS Hedge Fund Activity
We have seen 149 institutional investors add shares of ACADIA PHARMACEUTICALS stock to their portfolio, and 163 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 8,636,698 shares (+67.8%) to their portfolio in Q1 2025, for an estimated $143,455,553
- MORGAN STANLEY removed 2,616,866 shares (-35.9%) from their portfolio in Q1 2025, for an estimated $43,466,144
- STATE STREET CORP added 2,472,128 shares (+54.7%) to their portfolio in Q1 2025, for an estimated $41,062,046
- SG AMERICAS SECURITIES, LLC removed 2,465,581 shares (-99.3%) from their portfolio in Q1 2025, for an estimated $40,953,300
- POINT72 ASSET MANAGEMENT, L.P. added 2,417,001 shares (+108.3%) to their portfolio in Q1 2025, for an estimated $40,146,386
- ASSENAGON ASSET MANAGEMENT S.A. removed 1,951,550 shares (-53.3%) from their portfolio in Q2 2025, for an estimated $42,094,933
- AMERICAN CENTURY COMPANIES INC added 1,491,484 shares (+1055.8%) to their portfolio in Q1 2025, for an estimated $24,773,549
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ACADIA PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $ACAD in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 07/24/2025
- JMP Securities issued a "Market Outperform" rating on 06/26/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/26/2025
- Needham issued a "Buy" rating on 06/26/2025
- RBC Capital issued a "Outperform" rating on 06/23/2025
- Deutsche Bank issued a "Buy" rating on 05/21/2025
- BMO Capital issued a "Outperform" rating on 05/19/2025
To track analyst ratings and price targets for ACADIA PHARMACEUTICALS, check out Quiver Quantitative's $ACAD forecast page.
ACADIA PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $ACAD recently. We have seen 16 analysts offer price targets for $ACAD in the last 6 months, with a median target of $28.0.
Here are some recent targets:
- Tessa Romero from JP Morgan set a target price of $34.0 on 07/24/2025
- Jay Olson from Oppenheimer set a target price of $22.0 on 06/26/2025
- Jason Butler from JMP Securities set a target price of $37.0 on 06/26/2025
- Andrew Fein from HC Wainwright & Co. set a target price of $32.0 on 06/26/2025
- Ami Fadia from Needham set a target price of $30.0 on 06/26/2025
- Brian Abrahams from RBC Capital set a target price of $38.0 on 06/23/2025
- Tazeen Ahmad from B of A Securities set a target price of $23.0 on 06/05/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
